Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis

Abd-Elmawla et al., Journal of Zhejiang University-SCIENCE B, doi:10.1631/jzus.B2200385
Jul 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 110 treatments. c19ivm.org
Animal study showing that ivermectin alleviated pulmonary inflammation and fibrosis induced by bleomycin in a rat model. Authors note this may add to the clinical usefulness of ivermectin for patients with pulmonary fibrosis from COVID-19 or other causes. Results suggest that ivermectin's benefits in reducing lung inflammation and fibrosis involve inhibition of pro-inflammatory signaling pathways NLRP3 inflammasome, NF-kB, and HIF-1α.
70 preclinical studies support the efficacy of ivermectin for COVID-19:
Ivermectin, better known for antiparasitic activity, is a broad spectrum antiviral with activity against many viruses including H7N768, Dengue34,69,70, HIV-170, Simian virus 4071, Zika34,72,73, West Nile73, Yellow Fever74,75, Japanese encephalitis74, Chikungunya75, Semliki Forest virus75, Human papillomavirus54, Epstein-Barr54, BK Polyomavirus76, and Sindbis virus75.
Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins68,70,71,77, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing35, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination38,78, shows dose-dependent inhibition of wildtype and omicron variants33, exhibits dose-dependent inhibition of lung injury58,63, may inhibit SARS-CoV-2 via IMPase inhibition34, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation7, inhibits SARS-CoV-2 3CLpro51, may inhibit SARS-CoV-2 RdRp activity26, may minimize viral myocarditis by inhibiting NF-κB/p65-mediated inflammation in macrophages57, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation79, may interfere with SARS-CoV-2's immune evasion via ORF8 binding2, may inhibit SARS-CoV-2 by disrupting CD147 interaction80-83, shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-1956,84, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage6, may minimize SARS-CoV-2 induced cardiac damage37,45, increases Bifidobacteria which play a key role in the immune system85, has immunomodulatory48 and anti-inflammatory67,86 properties, and has an extensive and very positive safety profile87.
Abd-Elmawla et al., 1 Jul 2023, peer-reviewed, 5 authors. Contact: jzus_b@zju.edu.cn, heba.mosalam@pharma.cu.edu.eg, mei.abdelmawla@pharma.cu.edu.eg.
This PaperIvermectinAll
伊维菌素抑制NLRP3炎症小体可改善博来霉素诱导的肺纤维化
Mai A Abd-Elmawla, Heba R Ghaiad, Enas S Gad, Kawkab A Ahmed, Maha Abdelmonem
Journal of Zhejiang University-SCIENCE B, doi:10.1631/jzus.b2200385
Ivermectin is a US Food and Drug Administration (FDA)-approved antiparasitic agent with antiviral and anti-inflammatory properties. Although recent studies reported the possible anti-inflammatory activity of ivermectin in respiratory injuries, its potential therapeutic effect on pulmonary fibrosis (PF) has not been investigated. This study aimed to explore the ability of ivermectin (0.6 mg/kg) to alleviate bleomycin-induced biochemical derangements and histological changes in an experimental PF rat model. This can provide the means to validate the clinical utility of ivermectin as a treatment option for idiopathic PF. The results showed that ivermectin mitigated the bleomycin-evoked pulmonary injury, as manifested by the reduced infiltration of inflammatory cells, as well as decreased the inflammation and fibrosis scores. Intriguingly, ivermectin decreased collagen fiber deposition and suppressed transforming growth factor-β1 (TGF-β1) and fibronectin protein expression, highlighting its anti-fibrotic activity. This study revealed for the first time that ivermectin can suppress the nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome, as manifested by the reduced gene expression of NLRP3 and the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), with a subsequent decline in the interleukin-1β (IL-1β) level. In addition, ivermectin inhibited the expression of intracellular nuclear factor-κB (NF-κB) and hypoxia-inducible factor-1α (HIF-1α) proteins along with lowering the oxidative stress and apoptotic markers. Altogether, this study revealed that ivermectin could ameliorate pulmonary inflammation and fibrosis induced by bleomycin. These beneficial effects were mediated, at least partly, via the downregulation of TGF-β1 and fibronectin, as well as the suppression of NLRP3 inflammasome through modulating the expression of HIF-1α and NF-κB.
Author contributions All authors contributed to the study conception and design. Mai A. ABD-ELMAWLA, Heba R. GHAIAD, and Maha ABDELMONEM: study conception, material preparation, data collection & analysis, and writing; Enas S. GAD and Kawkab A. AHMED: material preparation, data collection & analysis, and writing. All authors wrote the first draft of the manuscript, and they all commented on previous versions of the manuscript. All authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data. The authors declare that all data were generated in-house and that no paper mill was used. Compliance with ethics guidelines Mai A. ABD-ELMAWLA, Heba R. GHAIAD, Enas S. GAD, Kawkab A. AHMED, and Maha ABDELMONEM declare that they have no conflict of interest. All institutional and national guidelines for the care and use of laboratory animals were followed. All animals' procedures were performed in accordance with the Research Ethics Committee of the Faculty of Pharmacy, Cairo University (REC-FOPCU), Egypt (No. BC3203) and with the Helsinki Declaration of 1975, as revised in 2013. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you..
References
Ambardar, Hightower, Huprikar, Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic, J Clin Med, doi:10.3390/jcm10112452
Blobe, Schiemann, Lodish, Role of transforming growth factor β in human disease, N Engl J Med, doi:10.1056/nejm200005043421807
Buonfrate, Bisoffi, Standard dose ivermectin for COVID-19, Chest, doi:10.1016/j.chest.2021.03.003
Caly, Druce, Catton, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Chen, Li, Inflammasome as an effective platform for fibrosis therapy, J Inflamm Res, doi:10.2147/JIR.S304180
Chen, Wang, Wang, Blockade of advanced glycation end product formation attenuates bleomycininduced pulmonary fibrosis in rats, Respir Res, doi:10.1186/1465-9921-10-55
Ci, Li, Yu, Avermectin exerts antiinflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol, doi:10.1111/j.1472-8206.2009.00684.x
Ding, Wei, Fu, Natural products that target the NLRP3 inflammasome to treat fibrosis, Front Pharmacol, doi:10.3389/fphar.2020.591393
Gad, Salama, El-Shafie, The anti-fibrotic and anti-inflammatory potential of bone marrow-derived mesenchymal stem cells and nintedanib in bleomycininduced lung fibrosis in rats, Inflammation, doi:10.1007/s10753-019-01101-2
Gazdhar, Susuri, Hostettler, HGF expressing stem cells in usual interstitial pneumonia originate from the bone marrow and are antifibrotic, PLoS ONE, doi:10.1371/journal.pone.0065453
Gonçalves, Vasconcelos, Barbirato, Therapeutic potential of ivermectin for COVID-19, doi:10.22541/au.159050476.60928563
Han, Jiang, He, Mefunidone ameliorates bleomycin-induced pulmonary fibrosis in mice, Front Pharmacol, doi:10.3389/fphar.2021.713572
Huang, Xia, Huang, HIF-1α promotes NLRP3 inflammasome activation in bleomycin-induced acute lung injury, Mol Med Rep, doi:10.3892/mmr.2019.10575
Jiang, Geng, Warren, Hypoxia inducible factor-1α (HIF-1α) mediates NLRP3 inflammasomedependent-pyroptotic and apoptotic cell death following ischemic stroke, Neuroscience, doi:10.1016/j.neuroscience.2020.09.036
Kan, Chen, Huang, Effect of Palrnatine on lipopolysaccharide-induced acute lung injury by inhibiting activation of the Akt/NF-κB pathway, J Zhejiang Univ-Sci B (Biomed & Biotechnol), doi:10.1631/jzus.B2000583
Kosyna, Nagel, Kluxen, The importin α/β-specific inhibitor ivermectin affects HIF-dependent hypoxia response pathways, Biol Chem, doi:10.1515/hsz-2015-0171
Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial, doi:10.1016/j.eclinm.2021.100959
Latz, Xiao, Stutz, Activation and regulation of the inflammasomes, Nat Rev Immunol, doi:10.1038/nri3452
Lechowicz, Drożdżal, Machaj, COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection, J Clin Med, doi:10.3390/jcm9061917
Lin, Barravecchia, Kottmann, Caveolin-1 gene therapy inhibits inflammasome activation to protect from bleomycin-induced pulmonary fibrosis, Sci Rep, doi:10.1038/s41598-019-55819-y
Liu, Lu, Kang, Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium, BMC Pulm Med, doi:10.1186/s12890-017-0405-7
Mansour, Shamma, Ahmed, Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: a preclinical tolerance study, Int Immunopharmacol, doi:10.1016/j.intimp.2021.108004
Mittal, Mittal, Inhaled route and anti-inflammatory action of ivermectin: do they hold promise in fighting against COVID-19?, Med Hypotheses, doi:10.1016/j.mehy.2020.110364
Raghu, Brown, Collard, Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial, Lancet Respir Med, doi:10.1016/S2213-2600(16)30421-0
Rodrigues, De Sá, Ishimoto, Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients, J Exp Med, doi:10.1084/jem.20201707
Ruiz-Riol, Berdnik, Llano, Identification of interleukin-27 (IL-27)/IL-27 receptor subunit alpha as a critical immune axis for in vivo HIV control, J Virol, doi:10.1128/jvi.00441-17
Sagoo, Garcia, Breart, In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity, Nat Med, doi:10.1038/nm.4016
Shin, Seol, Son, Interpretation of animal dose and human equivalent dose for drug development, J Korean Orient Med
Sia, Mensah, Opoku-Agyemang, Topical ivermectin 10 mg/g and oral doxycycline 40 mg modifiedrelease: current evidence on the complementary use of antiinflammatory rosacea treatments, BMC Vet Res, doi:10.1186/s12917-020-02612-z
Tian, Zhu, Yao, NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis, Exp Cell Res, doi:10.1016/j.yexcr.2017.05.028
Vriend, Reiter, Melatonin and the von Hippel-Lindau/ HIF-1 oxygen sensing mechanism: a review, Biochim Biophys Acta Rev Cancer, doi:10.1016/j.bbcan.2016.02.004
Wang, Li, Chen, Resveratrol alleviates bleomycin-induced pulmonary fibrosis via suppressing HIF-1α and NF-κB expression, Aging, doi:10.18632/aging.202420
Wang, Wang, Fang, Danggui Buxue Tang ameliorates bleomycin-induced pulmonary fibrosis by suppressing the TLR4/NLRP3 signaling pathway in rats, Evid Based Complement Alternat Med, doi:10.1155/2021/8030143
Zhang, Song, Ci, Ivermectin inhibits LPSinduced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflammation Res, doi:10.1007/s00011-008-8007-8
{ 'indexed': {'date-parts': [[2023, 7, 22]], 'date-time': '2023-07-22T19:28:16Z', 'timestamp': 1690054096061}, 'reference-count': 35, 'publisher': 'Zhejiang University Press', 'license': [ { 'start': { 'date-parts': [[2023, 7, 1]], 'date-time': '2023-07-01T00:00:00Z', 'timestamp': 1688169600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2023, 7, 1]], 'date-time': '2023-07-01T00:00:00Z', 'timestamp': 1688169600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Ivermectin is a US Food and Drug Administration ' '(FDA)-approved antiparasitic agent with antiviral and anti-inflammatory properties. Although ' 'recent studies reported the possible anti-inflammatory activity of ivermectin in respiratory ' 'injuries, its potential therapeutic effect on pulmonary fibrosis (PF) has not been ' 'investigated. This study aimed to explore the ability of ivermectin (0.6 mg/kg) to alleviate ' 'bleomycin-induced biochemical derangements and histological changes in an experimental PF rat ' 'model. This can provide the means to validate the clinical utility of ivermectin as a ' 'treatment option for idiopathic PF. The results showed that ivermectin mitigated the ' 'bleomycin-evoked pulmonary injury, as manifested by the reduced infiltration of inflammatory ' 'cells, as well as decreased the inflammation and fibrosis scores. Intriguingly, ivermectin ' 'decreased collagen fiber deposition and suppressed transforming growth factor-β1 (TGF-β1) and ' 'fibronectin protein expression, highlighting its anti-fibrotic activity. This study revealed ' 'for the first time that ivermectin can suppress the nucleotide-binding oligomerization domain ' '(NOD)-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome, as ' 'manifested by the reduced gene expression of <jats:italic>NLRP3</jats:italic> and the ' 'apoptosis-associated speck-like protein containing a caspase recruitment domain ' '(<jats:italic>ASC</jats:italic>), with a subsequent decline in the interleukin-1β (IL-1β) ' 'level. In addition, ivermectin inhibited the expression of intracellular nuclear factor-κB ' '(NF-κB) and hypoxia-inducible factor-1α (HIF-1α) proteins along with lowering the oxidative ' 'stress and apoptotic markers. Altogether, this study revealed that ivermectin could ' 'ameliorate pulmonary inflammation and fibrosis induced by bleomycin. These beneficial effects ' 'were mediated, at least partly, via the downregulation of TGF-β1 and fibronectin, as well as ' 'the suppression of NLRP3 inflammasome through modulating the expression of HIF-1α and ' 'NF-κB.</jats:p>', 'DOI': '10.1631/jzus.b2200385', 'type': 'journal-article', 'created': {'date-parts': [[2023, 7, 1]], 'date-time': '2023-07-01T00:01:59Z', 'timestamp': 1688169719000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': '伊维菌素抑制NLRP3炎症小体可改善博来霉素诱导的肺纤维化', 'prefix': '10.1631', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7582-7617', 'authenticated-orcid': False, 'given': 'Mai A.', 'family': 'Abd-Elmawla', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-4765-0353', 'authenticated-orcid': False, 'given': 'Heba R.', 'family': 'Ghaiad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Enas S.', 'family': 'Gad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kawkab A.', 'family': 'Ahmed', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maha', 'family': 'Abdelmonem', 'sequence': 'additional', 'affiliation': []}], 'member': '635', 'published-online': {'date-parts': [[2023, 7, 1]]}, 'reference': [ { 'issue': '11', 'key': '38_CR1', 'doi-asserted-by': 'publisher', 'first-page': '2452', 'DOI': '10.3390/jcm10112452', 'volume': '10', 'author': 'SR Ambardar', 'year': '2021', 'unstructured': 'Ambardar SR, Hightower SL, Huprikar NA, et al., 2021. Post-COVID-19 ' 'pulmonary fibrosis: novel sequelae of the current pandemic. J Clin Med, ' '10(11):2452. https://doi.org/10.3390/jcm10112452', 'journal-title': 'J Clin Med'}, { 'issue': '18', 'key': '38_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1350', 'DOI': '10.1056/NEJM200005043421807', 'volume': '342', 'author': 'GC Blobe', 'year': '2000', 'unstructured': 'Blobe GC, Schiemann WP, Lodish HF, 2000. Role of transforming growth ' 'factor β in human disease. N Engl J Med, 342(18):1350–1358. ' 'https://doi.org/10.1056/nejm200005043421807', 'journal-title': 'N Engl J Med'}, { 'issue': '5', 'key': '38_CR3', 'doi-asserted-by': 'publisher', 'first-page': '2111', 'DOI': '10.1016/j.chest.2021.03.003', 'volume': '159', 'author': 'D Buonfrate', 'year': '2021', 'unstructured': 'Buonfrate D, Bisoffi Z, 2021. Standard dose ivermectin for COVID-19. ' 'Chest, 159(5):2111–2112. https://doi.org/10.1016/j.chest.2021.03.003', 'journal-title': 'Chest'}, { 'key': '38_CR4', 'doi-asserted-by': 'publisher', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'volume': '178', 'author': 'L Caly', 'year': '2020', 'unstructured': 'Caly L, Druce JD, Catton MG, et al., 2020. The FDA-approved drug ' 'ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral ' 'Res, 178:104787. https://doi.org/10.1016/j.antiviral.2020.104787', 'journal-title': 'Antiviral Res'}, { 'key': '38_CR5', 'doi-asserted-by': 'publisher', 'first-page': '55', 'DOI': '10.1186/1465-9921-10-55', 'volume': '10', 'author': 'L Chen', 'year': '2009', 'unstructured': 'Chen L, Wang T, Wang X, et al., 2009. Blockade of advanced glycation end ' 'product formation attenuates bleomycin-induced pulmonary fibrosis in ' 'rats. Respir Res, 10:55. https://doi.org/10.1186/1465-9921-10-55', 'journal-title': 'Respir Res'}, { 'key': '38_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1575', 'DOI': '10.2147/JIR.S304180', 'volume': '14', 'author': 'TT Chen', 'year': '2021', 'unstructured': 'Chen TT, Xiao F, Li N, et al., 2021. Inflammasome as an effective ' 'platform for fibrosis therapy. J Inflamm Res, 14:1575–1590. ' 'https://doi.org/10.2147/JIR.S304180', 'journal-title': 'J Inflamm Res'}, { 'issue': '4', 'key': '38_CR7', 'doi-asserted-by': 'publisher', 'first-page': '449', 'DOI': '10.1111/j.1472-8206.2009.00684.x', 'volume': '23', 'author': 'XX Ci', 'year': '2009', 'unstructured': 'Ci XX, Li HY, Yu QL, et al., 2009. Avermectin exerts anti-inflammatory ' 'effect by downregulating the nuclear transcription factor kappa-B and ' 'mitogen-activated protein kinase activation pathway. Fundam Clin ' 'Pharmacol, 23(4): 449–455. ' 'https://doi.org/10.1111/j.1472-8206.2009.00684.x', 'journal-title': 'Fundam Clin Pharmacol'}, { 'key': '38_CR8', 'doi-asserted-by': 'publisher', 'first-page': '591393', 'DOI': '10.3389/fphar.2020.591393', 'volume': '11', 'author': 'N Ding', 'year': '2020', 'unstructured': 'Ding N, Wei B, Fu XH, et al., 2020. Natural products that target the ' 'NLRP3 inflammasome to treat fibrosis. Front Pharmacol, 11:591393. ' 'https://doi.org/10.3389/fphar.2020.591393', 'journal-title': 'Front Pharmacol'}, { 'issue': '1', 'key': '38_CR9', 'doi-asserted-by': 'publisher', 'first-page': '123', 'DOI': '10.1007/s10753-019-01101-2', 'volume': '43', 'author': 'ES Gad', 'year': '2020', 'unstructured': 'Gad ES, Salama AAA, El-Shafie MF, et al., 2020. The anti-fibrotic and ' 'anti-inflammatory potential of bone marrow-derived mesenchymal stem ' 'cells and nintedanib in bleomycin-induced lung fibrosis in rats. ' 'Inflammation, 43(1):123–134. https://doi.org/10.1007/s10753-019-01101-2', 'journal-title': 'Inflammation'}, { 'issue': '6', 'key': '38_CR10', 'doi-asserted-by': 'publisher', 'first-page': 'e65453', 'DOI': '10.1371/journal.pone.0065453', 'volume': '8', 'author': 'A Gazdhar', 'year': '2013', 'unstructured': 'Gazdhar A, Susuri N, Hostettler K, et al., 2013. HGF expressing stem ' 'cells in usual interstitial pneumonia originate from the bone marrow and ' 'are antifibrotic. PLoS ONE, 8(6): e65453. ' 'https://doi.org/10.1371/journal.pone.0065453', 'journal-title': 'PLoS ONE'}, { 'key': '38_CR11', 'doi-asserted-by': 'publisher', 'unstructured': 'Gonçalves K, Vasconcelos A, Barbirato D, et al., 2020. Therapeutic ' 'potential of ivermectin for COVID-19. Authorea, preprint. ' 'https://doi.org/10.22541/au.159050476.60928563', 'DOI': '10.22541/au.159050476.60928563'}, { 'key': '38_CR12', 'doi-asserted-by': 'publisher', 'first-page': '713572', 'DOI': '10.3389/fphar.2021.713572', 'volume': '12', 'author': 'YY Han', 'year': '2021', 'unstructured': 'Han YY, Jiang M, He RL, et al., 2021. Mefunidone ameliorates ' 'bleomycin-induced pulmonary fibrosis in mice. Front Pharmacol, ' '12:713572. https://doi.org/10.3389/fphar.2021.713572', 'journal-title': 'Front Pharmacol'}, { 'issue': '4', 'key': '38_CR13', 'doi-asserted-by': 'publisher', 'first-page': '3424', 'DOI': '10.3892/mmr.2019.10575', 'volume': '20', 'author': 'JJ Huang', 'year': '2019', 'unstructured': 'Huang JJ, Xia J, Huang LL, et al., 2019. HIF-1α promotes NLRP3 ' 'inflammasome activation in bleomycin-induced acute lung injury. Mol Med ' 'Rep, 20(4):3424–3432. https://doi.org/10.3892/mmr.2019.10575', 'journal-title': 'Mol Med Rep'}, { 'key': '38_CR14', 'doi-asserted-by': 'publisher', 'first-page': '126', 'DOI': '10.1016/j.neuroscience.2020.09.036', 'volume': '448', 'author': 'Q Jiang', 'year': '2020', 'unstructured': 'Jiang Q, Geng XK, Warren J, et al., 2020. Hypoxia inducible factor-1α ' '(HIF-1α) mediates NLRP3 inflammasome-dependent-pyroptotic and apoptotic ' 'cell death following ischemic stroke. Neuroscience, 448:126–139. ' 'https://doi.org/10.1016/j.neuroscience.2020.09.036', 'journal-title': 'Neuroscience'}, { 'issue': '11', 'key': '38_CR15', 'doi-asserted-by': 'publisher', 'first-page': '929', 'DOI': '10.1631/jzus.B2000583', 'volume': '22', 'author': 'XC Kan', 'year': '2021', 'unstructured': 'Kan XC, Chen YS, Huang BX, et al., 2021. Effect of Palrnatine on ' 'lipopolysaccharide-induced acute lung injury by inhibiting activation of ' 'the Akt/NF-κB pathway. J Zhejiang Univ-Sci B (Biomed & Biotechnol), ' '22(11):929–940. https://doi.org/10.1631/jzus.B2000583', 'journal-title': 'J Zhejiang Univ-Sci B (Biomed & Biotechnol)'}, { 'issue': '12', 'key': '38_CR16', 'doi-asserted-by': 'publisher', 'first-page': '1357', 'DOI': '10.1515/hsz-2015-0171', 'volume': '396', 'author': 'FK Kosyna', 'year': '2015', 'unstructured': 'Kosyna FK, Nagel M, Kluxen L, et al., 2015. The importin α/β-specific ' 'inhibitor ivermectin affects HIF-dependent hypoxia response pathways. ' 'Biol Chem, 396(12):1357–1367. https://doi.org/10.1515/hsz-2015-0171', 'journal-title': 'Biol Chem'}, { 'key': '38_CR17', 'doi-asserted-by': 'publisher', 'first-page': '100959', 'DOI': '10.1016/j.eclinm.2021.100959', 'volume': '37', 'author': 'A Krolewiecki', 'year': '2021', 'unstructured': 'Krolewiecki A, Lifschitz A, Moragas M, et al., 2021. Antiviral effect of ' 'high-dose ivermectin in adults with COVID-19: a proof-of-concept ' 'randomized trial. eClinicalMedicine, 37:100959. ' 'https://doi.org/10.1016/j.eclinm.2021.100959', 'journal-title': 'eClinicalMedicine'}, { 'issue': '6', 'key': '38_CR18', 'doi-asserted-by': 'publisher', 'first-page': '397', 'DOI': '10.1038/nri3452', 'volume': '13', 'author': 'E Latz', 'year': '2013', 'unstructured': 'Latz E, Xiao TS, Stutz A, 2013. Activation and regulation of the ' 'inflammasomes. Nat Rev Immunol, 13(6):397–411. ' 'https://doi.org/10.1038/nri3452', 'journal-title': 'Nat Rev Immunol'}, { 'issue': '6', 'key': '38_CR19', 'doi-asserted-by': 'publisher', 'first-page': '1917', 'DOI': '10.3390/jcm9061917', 'volume': '9', 'author': 'K Lechowicz', 'year': '2020', 'unstructured': 'Lechowicz K, Drożdżal S, Machaj F, et al., 2020. COVID-19: the potential ' 'treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J ' 'Clin Med, 9(6):1917. https://doi.org/10.3390/jcm9061917', 'journal-title': 'J Clin Med'}, { 'key': '38_CR20', 'doi-asserted-by': 'publisher', 'first-page': '19643', 'DOI': '10.1038/s41598-019-55819-y', 'volume': '9', 'author': 'X Lin', 'year': '2019', 'unstructured': 'Lin X, Barravecchia M, Kottmann RM, et al., 2019. Caveolin-1 gene ' 'therapy inhibits inflammasome activation to protect from ' 'bleomycin-induced pulmonary fibrosis. Sci Rep, 9: 19643. ' 'https://doi.org/10.1038/s41598-019-55819-y', 'journal-title': 'Sci Rep'}, { 'key': '38_CR21', 'doi-asserted-by': 'publisher', 'first-page': '63', 'DOI': '10.1186/s12890-017-0405-7', 'volume': '17', 'author': 'Y Liu', 'year': '2017', 'unstructured': 'Liu Y, Lu FA, Kang LR, et al., 2017. Pirfenidone attenuates ' 'bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 ' 'equilibrium. BMC Pulm Med, 17:63. ' 'https://doi.org/10.1186/s12890-017-0405-7', 'journal-title': 'BMC Pulm Med'}, { 'key': '38_CR22', 'doi-asserted-by': 'publisher', 'first-page': '108004', 'DOI': '10.1016/j.intimp.2021.108004', 'volume': '99', 'author': 'SM Mansour', 'year': '2021', 'unstructured': 'Mansour SM, Shamma RN, Ahmed KA, et al., 2021. Safety of inhaled ' 'ivermectin as a repurposed direct drug for treatment of COVID-19: a ' 'preclinical tolerance study. Int Immunopharmacol, 99:108004. ' 'https://doi.org/10.1016/j.intimp.2021.108004', 'journal-title': 'Int Immunopharmacol'}, { 'key': '38_CR23', 'doi-asserted-by': 'publisher', 'first-page': '110364', 'DOI': '10.1016/j.mehy.2020.110364', 'volume': '146', 'author': 'N Mittal', 'year': '2021', 'unstructured': 'Mittal N, Mittal R, 2021. Inhaled route and anti-inflammatory action of ' 'ivermectin: do they hold promise in fighting against COVID-19? Med ' 'Hypotheses, 146:110364. https://doi.org/10.1016/j.mehy.2020.110364', 'journal-title': 'Med Hypotheses'}, { 'issue': '1', 'key': '38_CR24', 'doi-asserted-by': 'publisher', 'first-page': '22', 'DOI': '10.1016/S2213-2600(16)30421-0', 'volume': '5', 'author': 'G Raghu', 'year': '2017', 'unstructured': 'Raghu G, Brown KK, Collard HR, et al., 2017. Efficacy of simtuzumab ' 'versus placebo in patients with idiopathic pulmonary fibrosis: a ' 'randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med, ' '5(1):22–32. https://doi.org/10.1016/S2213-2600(16)30421-0', 'journal-title': 'Lancet Respir Med'}, { 'issue': '3', 'key': '38_CR25', 'doi-asserted-by': 'publisher', 'first-page': 'e20201707', 'DOI': '10.1084/jem.20201707', 'volume': '218', 'author': 'TS Rodrigues', 'year': '2021', 'unstructured': 'Rodrigues TS, de Sá KSG, Ishimoto AY, et al., 2021. Inflammasomes are ' 'activated in response to SARS-CoV-2 infection and are associated with ' 'COVID-19 severity in patients. J Exp Med, 218(3):e20201707. ' 'https://doi.org/10.1084/jem.20201707', 'journal-title': 'J Exp Med'}, { 'issue': '16', 'key': '38_CR26', 'doi-asserted-by': 'publisher', 'first-page': 'e00441', 'DOI': '10.1128/JVI.00441-17', 'volume': '91', 'author': 'M Ruiz-Riol', 'year': '2017', 'unstructured': 'Ruiz-Riol M, Berdnik D, Llano A, et al., 2017. Identification of ' 'interleukin-27 (IL-27)/IL-27 receptor subunit alpha as a critical immune ' 'axis for in vivo HIV control. J Virol, 91(16):e00441–17. ' 'https://doi.org/10.1128/jvi.00441-17', 'journal-title': 'J Virol'}, { 'issue': '1', 'key': '38_CR27', 'doi-asserted-by': 'publisher', 'first-page': '64', 'DOI': '10.1038/nm.4016', 'volume': '22', 'author': 'P Sagoo', 'year': '2016', 'unstructured': 'Sagoo P, Garcia Z, Breart B, et al., 2016. In vivo imaging of ' 'inflammasome activation reveals a subcapsular macrophage burst response ' 'that mobilizes innate and adaptive immunity. Nat Med, 22(1):64–71. ' 'https://doi.org/10.1038/nm.4016', 'journal-title': 'In vivo imaging of inflammasome activation reveals a subcapsular ' 'macrophage burst response that mobilizes innate and adaptive immunity. ' 'Nat Med'}, { 'issue': '3', 'key': '38_CR28', 'first-page': '1', 'volume': '31', 'author': 'JW Shin', 'year': '2010', 'unstructured': 'Shin JW, Seol IC, Son CG, 2010. Interpretation of animal dose and human ' 'equivalent dose for drug development. J Korean Orient Med, 31(3):1–7.', 'journal-title': 'J Korean Orient Med'}, { 'key': '38_CR29', 'doi-asserted-by': 'publisher', 'first-page': '397', 'DOI': '10.1186/s12917-020-02612-z', 'volume': '16', 'author': 'DK Sia', 'year': '2020', 'unstructured': 'Sia DK, Mensah KB, Opoku-Agyemang T, et al., 2020. Mechanisms of ' 'ivermectin-induced wound healing. BMC Vet Res, 16:397. ' 'https://doi.org/10.1186/s12917-020-02612-z', 'journal-title': 'BMC Vet Res'}, { 'key': '38_CR30', 'doi-asserted-by': 'publisher', 'first-page': '1481', 'DOI': '10.1007/s12325-016-0380-z', 'volume': '33', 'author': 'M Steinhoff', 'year': '2016', 'unstructured': 'Steinhoff M, Vocanson M, Voegel JJ, et al., 2016. Topical ivermectin 10 ' 'mg/g and oral doxycycline 40 mg modified-release: current evidence on ' 'the complementary use of anti-inflammatory rosacea treatments. Adv Ther, ' '33:1481–1501. https://doi.org/10.1007/s12325-016-0380-z', 'journal-title': 'Adv Ther'}, { 'issue': '2', 'key': '38_CR31', 'doi-asserted-by': 'publisher', 'first-page': '328', 'DOI': '10.1016/j.yexcr.2017.05.028', 'volume': '357', 'author': 'R Tian', 'year': '2017', 'unstructured': 'Tian R, Zhu Y, Yao JY, et al., 2017. NLRP3 participates in the ' 'regulation of EMT in bleomycin-induced pulmonary fibrosis. Exp Cell Res, ' '357(2):328–334. https://doi.org/10.1016/j.yexcr.2017.05.028', 'journal-title': 'Exp Cell Res'}, { 'issue': '2', 'key': '38_CR32', 'doi-asserted-by': 'publisher', 'first-page': '176', 'DOI': '10.1016/j.bbcan.2016.02.004', 'volume': '1865', 'author': 'J Vriend', 'year': '2016', 'unstructured': 'Vriend J, Reiter RJ, 2016. Melatonin and the von Hippel–Lindau/HIF-1 ' 'oxygen sensing mechanism: a review. Biochim Biophys Acta Rev Cancer, ' '1865(2):176–183. https://doi.org/10.1016/j.bbcan.2016.02.004', 'journal-title': 'Biochim Biophys Acta Rev Cancer'}, { 'key': '38_CR33', 'doi-asserted-by': 'publisher', 'first-page': '8030143', 'DOI': '10.1155/2021/8030143', 'volume': '2021', 'author': 'JP Wang', 'year': '2021', 'unstructured': 'Wang JP, Wang H, Fang F, et al., 2021. Danggui Buxue Tang ameliorates ' 'bleomycin-induced pulmonary fibrosis by suppressing the TLR4/NLRP3 ' 'signaling pathway in rats. Evid Based Complement Alternat Med, ' '2021:8030143. https://doi.org/10.1155/2021/8030143', 'journal-title': 'Evid Based Complement Alternat Med'}, { 'issue': '3', 'key': '38_CR34', 'doi-asserted-by': 'publisher', 'first-page': '4605', 'DOI': '10.18632/aging.202420', 'volume': '13', 'author': 'ZY Wang', 'year': '2021', 'unstructured': 'Wang ZY, Li XN, Chen H, et al., 2021. Resveratrol alleviates ' 'bleomycin-induced pulmonary fibrosis via suppressing HIF-1α and NF-κB ' 'expression. Aging, 13(3):4605–4616. ' 'https://doi.org/10.18632/aging.202420', 'journal-title': 'Aging'}, { 'issue': '11', 'key': '38_CR35', 'doi-asserted-by': 'publisher', 'first-page': '524', 'DOI': '10.1007/s00011-008-8007-8', 'volume': '57', 'author': 'X Zhang', 'year': '2008', 'unstructured': 'Zhang X, Song Y, Ci X, et al., 2008. Ivermectin inhibits LPS-induced ' 'production of inflammatory cytokines and improves LPS-induced survival ' 'in mice. Inflammation Res, 57(11):524–529. ' 'https://doi.org/10.1007/s00011-008-8007-8', 'journal-title': 'Inflammation Res'}], 'container-title': 'Journal of Zhejiang University-SCIENCE B', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1631/jzus.B2200385.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1631/jzus.B2200385/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1631/jzus.B2200385.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 7, 1]], 'date-time': '2023-07-01T00:02:02Z', 'timestamp': 1688169722000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1631/jzus.B2200385'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 7, 1]]}, 'references-count': 35, 'alternative-id': ['38'], 'URL': 'http://dx.doi.org/10.1631/jzus.B2200385', 'relation': {}, 'ISSN': ['1673-1581', '1862-1783'], 'subject': [ 'General Pharmacology, Toxicology and Pharmaceutics', 'General Veterinary', 'General Biochemistry, Genetics and Molecular Biology', 'General Medicine'], 'container-title-short': 'J. Zhejiang Univ. Sci. B', 'published': {'date-parts': [[2023, 7, 1]]}, 'assertion': [ { 'value': '31 July 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '11 December 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '1 July 2023', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit